# US 2010/0168165 A1 · Method of treating disease involving myelin and/or axonal loss

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168165 A1
- Document ID: US20100168165A1
- Status: Published application
- Kind: A1
- Application number: 12/706,068
- Filed: 2010-02-16
- Published: 2010-07-01
- Earliest claimed: 2007-08-14
- Assignees: The United States of America, as represented by the Secretary, Dept. of Health and Human Services
- Inventors: Jacqueline A. Quandt; James B. Mitchell; Anastasia Sowers; Murali Krishna Cherukuri
- Web page: https://patentgrep.com/patent/US20100168165A1

## CPC

- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/444: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A61K 31/45: having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/00: Drugs for immunological or allergic disorders
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed is a method of treating a disease involving myelin and/or axonal loss, such as a demyelinating disease, in a mammal comprising administering a compound of formula I in which R1-R11 and n are defined herein. Also disclosed are methods of using a compound of formula I to treat neurodegeneration associated with inflammation and to reduce myelin and/or axonal loss.

## Claims

### Claim 1

A method of treating a disease involving myelin and/or axonal loss in a mammal comprising administering to the mammal an effective amount of a compound of formula I
wherein
R1 is selected from the group consisting of OH, OZ, O, and ═O,
wherein Z is selected from the group consisting of C1-12 alkyl, C2-12 alkenyl, C3-8 cycloalkyl, C3-8 heterocycloalkyl, and C6-30 aryl;
R2, R3, R4, and R5 are the same or different and are selected from the group consisting of hydrogen, C1-12 alkyl, C2-12 alkenyl, and C2-12 alkynyl;
R6 and R7 are the same or different and are selected from the group consisting of hydrogen, halogen, hydroxyl, thiol, cyano, —NCS, C1-12 alkyl, C2-12 alkenyl, C3-8 cycloalkyl, C3-8 heterocycloalkyl, C6-30 aryl, C1-12 alkoxy, C1-12 alkylthio, amino, alkylamino, dialkylamino, arylamino, diarylamino, alkylsulfonyloxy, carboxyl, alkylcarbonyl, arylcarbonyl, hydroxyalkyl, mercaptoalkyl, carboxyalkyl, carboxyaryl, alkylcarbonylalkyl, alkylcarbonylaryl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, arylaminoalkyl, diarylaminoalkyl, alkylcarbonylamino, and haloalkylcarbonylamino, or
R6 and R7 together form ═O;
R8, R9, R10, and R11 are the same or different and are selected from the group consisting of hydrogen, halogen, hydroxyl, thiol, cyano, —NCS, C1-12 alkyl, C2-12 alkenyl, C3-8 cycloalkyl, C3-8 heterocycloalkyl, C6-30 aryl, C1-12 alkoxy, C1-12 alkylthio, amino, alkylamino, dialkylamino, arylamino, diarylamino, alkylsulfonyloxy, carboxyl, alkylcarbonyl, arylcarbonyl, hydroxyalkyl, mercaptoalkyl, carboxyalkyl, carboxyaryl, alkylcarbonylalkyl, alkylcarbonylaryl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, arylaminoalkyl, diarylaminoalkyl, alkylcarbonylamino, and haloalkylcarbonylamino;
optionally one of R6 and R7 and one of R8 and R9 can be absent such that a double bond joins the two carbon atoms to which the remaining of one of R6 and R7 and one of R8 and R9 are attached; and
n is 0 or 1;
provided that the disease is not ataxia telangiectasia (AT).

### Claim 2 (depends on 1)

The method of claim 1, wherein the disease is a demyelinating disease.

### Claim 3 (depends on 1)

The method of claim 1, wherein the disease involves axonal damage or impairment.

### Claim 4 (depends on 1)

The method of claim 1, wherein the disease is an inflammatory disease.

### Claim 5 (depends on 1)

The method of claim 1, wherein an autoimmune component of the disease is treated.

### Claim 6 (depends on 1)

The method of claim 1, wherein the disease is multiple sclerosis (MS), optic neuritis, Devic's disease (neuromyelitis optica), transverse myelitis, acute MS (Marburg variant), Balo's concentric sclerosis, Guillain-Barré syndrome, acute disseminated encephalomyelitis (ADEM), adrenoleukodystrophy, or adrenomyeloneuropathy.

### Claim 7 (depends on 6)

The method of claim 6, wherein the disease is multiple sclerosis (MS).

### Claim 8

A method of treating neurodegeneration associated with inflammation in a mammal comprising administering to the mammal an effective amount of a compound of formula I
wherein
R1 is selected from the group consisting of OH, OZ, O, and ═O,
wherein Z is selected from the group consisting of C1-12 alkyl, C2-12 alkenyl, C3-8 cycloalkyl, C3-8 heterocycloalkyl, and C6-30 aryl;
R2, R3, R4, and R5 are the same or different and are selected from the group consisting of hydrogen, C1-12 alkyl, C2-12 alkenyl, and C2-12 alkynyl;
R6 and R7 are the same or different and are selected from the group consisting of hydrogen, halogen, hydroxyl, thiol, cyano, —NCS, C1-12 alkyl, C2-12 alkenyl, C3-8 cycloalkyl, C3-8 heterocycloalkyl, C6-30 aryl, C1-12 alkoxy, C1-12 alkylthio, amino, alkylamino, dialkylamino, arylamino, diarylamino, alkylsulfonyloxy, carboxyl, alkylcarbonyl, arylcarbonyl, hydroxyalkyl, mercaptoalkyl, carboxyalkyl, carboxyaryl, alkylcarbonylalkyl, alkylcarbonylaryl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, arylaminoalkyl, diarylaminoalkyl, alkylcarbonylamino, and haloalkylcarbonylamino, or
R6 and R7 together form ═O;
R8, R9, R10, and R11 are the same or different and are selected from the group consisting of hydrogen, halogen, hydroxyl, thiol, cyano, —NCS, C1-12 alkyl, C2-12 alkenyl, C3-8 cycloalkyl, C3-8 heterocycloalkyl, C6-30 aryl, C1-12 alkoxy, C1-12 alkylthio, amino, alkylamino, dialkylamino, arylamino, diarylamino, alkylsulfonyloxy, carboxyl, alkylcarbonyl, arylcarbonyl, hydroxyalkyl, mercaptoalkyl, carboxyalkyl, carboxyaryl, alkylcarbonylalkyl, alkylcarbonylaryl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, arylaminoalkyl, diarylaminoalkyl, alkylcarbonylamino, and haloalkylcarbonylamino;
optionally one of R6 and R7 and one of R8 and R9 can be absent such that a double bond joins the two carbon atoms to which the remaining of one of R6 and R7 and one of R8 and R9 are attached; and
n is 0 or 1;
provided that the neurodegeneration is not caused by ataxia telangiectasia (AT).

### Claim 9 (depends on 8)

The method of claim 8, wherein the compound of formula I provides protection against onset and progression of neurodegeneration of the central nervous system (CNS).

### Claim 10 (depends on 8)

The method of claim 8, wherein the neurodegeneration is caused by multiple sclerosis (MS), optic neuritis, Devic's disease (neuromyelitis optica), transverse myelitis, acute MS (Marburg variant), Balo's concentric sclerosis, Guillain-Barré syndrome, acute disseminated encephalomyelitis (ADEM), adrenoleukodystrophy, or adrenomyeloneuropathy.

### Claim 11 (depends on 10)

The method of claim 10, wherein the neurodegeneration is caused by multiple sclerosis (MS).

### Claim 12

A method of reducing myelin and/or axonal loss in a mammal comprising administering to the mammal an effective amount of a compound of formula I
wherein
R1 is selected from the group consisting of OH, OZ, O, and ═O,
wherein Z is selected from the group consisting of C1-12 alkyl, C2-12 alkenyl, C3-8 cycloalkyl, C3-8 heterocycloalkyl, and C6-30 aryl;
R2, R3, R4, and R5 are the same or different and are selected from the group consisting of hydrogen, C1-12 alkyl, C2-12 alkenyl, and C2-12 alkynyl;
hydrogen, halogen, hydroxyl, thiol, cyano, —NCS, C1-12 alkyl, C2-12 alkenyl, C3-8 cycloalkyl, C3-8 heterocycloalkyl, C6-30 aryl, C1-12 alkoxy, C1-12 alkylthio, amino, alkylamino, dialkylamino, arylamino, diarylamino, alkylsulfonyloxy, carboxyl, alkylcarbonyl, arylcarbonyl, hydroxyalkyl, mercaptoalkyl, carboxyalkyl, carboxyaryl, alkylcarbonylalkyl, alkylcarbonylaryl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, arylaminoalkyl, diarylaminoalkyl, alkylcarbonylamino, and haloalkylcarbonylamino, or
R6 and R7 together form ═O;
R8, R9, R10, and R11 are the same or different and are selected from the group consisting of hydrogen, halogen, hydroxyl, thiol, cyano, —NCS, C1-12 alkyl, C2-12 alkenyl, C3-8 cycloalkyl, C3-8 heterocycloalkyl, C6-30 aryl, C1-12 alkoxy, C1-12 alkylthio, amino, alkylamino, dialkylamino, arylamino, diarylamino, alkylsulfonyloxy, carboxyl, alkylcarbonyl, arylcarbonyl, hydroxyalkyl, mercaptoalkyl, carboxyalkyl, carboxyaryl, alkylcarbonylalkyl, alkylcarbonylaryl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, arylaminoalkyl, diarylaminoalkyl, alkylcarbonylamino, and haloalkylcarbonylamino;
optionally one of R6 and R7 and one of R8 and R9 can be absent such that a double bond joins the two carbon atoms to which the remaining of one of R6 and R7 and one of R8 and R9 are attached; and
n is 0 or 1.

### Claim 13 (depends on 1)

The method of claim 1, wherein R1 is O.

### Claim 14 (depends on 1)

The method of claim 1, wherein R2, R3, R4, and R5 are C1-12 alkyl.

### Claim 15 (depends on 1)

The method of claim 1, wherein R2, R3, R4, and R5 are C1-4 alkyl.

### Claim 16 (depends on 1)

The method of claim 1, wherein R2, R3, R4, and R5 are methyl.

### Claim 17 (depends on 1)

The method of claim 1, wherein R7 is selected from the group consisting of hydrogen, halogen, hydroxyl, and C1-12 alkyl.

### Claim 18 (depends on 1)

The method of claim 1, wherein R7 is hydrogen.

### Claim 19 (depends on 1)

The method of claim 1, wherein R8, R9, R10, and R11 are the same or different and each is selected from the group consisting of hydrogen, halogen, hydroxyl, and C1-12 alkyl.

### Claim 20 (depends on 1)

The method of claim 1, wherein R8, R9, R10, and R11 are hydrogen.

### Claim 21 (depends on 1)

The method of claim 1, wherein R6 is hydrogen, hydroxyl, C1-12 alkyl, C1-12 alkoxy, cyano, isothiocyanato, amino, carboxy, alkylcarbonylamino, haloalkylcarbonylamino, or alkylsulfonyloxy.

### Claim 22 (depends on 1)

The method of claim 1, wherein R6 is hydroxyl.

### Claim 23 (depends on 1)

The method of claim 1, wherein n is 1.

### Claim 24 (depends on 1)

The method of claim 1, wherein the compound of formula I is selected from the group consisting of
4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl (Tempol),
2,2,6,6-tetramethylpiperidine-1-oxyl (Tempo),
4-methoxy-2,2,6,6-tetramethyl-1-piperidine-1-oxyl,
4-carboxy-2,2,6,6-tetramethyl-1-piperidine-1-oxyl,
4-oxo-2,2,6,6-tetramethyl-1-piperidine-1-oxyl,
4-amino-2,2,6,6-tetramethyl-1-piperidine-1-oxyl,
4-cyano-2,2,6,6-tetramethyl-1-piperidine-1-oxyl,
4-isocyanato-2,2,6,6-tetramethyl-1-piperidine-1-oxyl,
4-acetamido-2,2,6,6-tetramethyl-1-piperidine-1-oxyl,
4-(2-bromoacetamido)-2,2,6,6-tetramethyl-1-piperidine-1-oxyl,
4-(2-chloroacetamido)-2,2,6,6-tetramethyl-1-piperidine-1-oxyl,
4-(2-iodoacetamido)-2,2,6,6-tetramethyl-1-piperidine-1-oxyl, and
4-(methylsulfonyloxy)-2,2,6,6-tetramethyl-1-piperidine-1-oxyl.

### Claim 25 (depends on 1)

The method of claim 1, wherein the compound of formula I is 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl (Tempol).

### Claim 26 (depends on 1)

The method of claim 1, wherein the mammal is a human.

### Claim 27 (depends on 1)

The method of claim 1, wherein the compound of formula I is administered orally.

### Claim 28 (depends on 27)

The method of claim 27, wherein the compound of formula I is administered with food.
